SAShoaib Al-Zadjali

Shoaib Al-Zadjali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shoaib Al-Zadjali has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extracellular Vesicle Associated Proteomic Biomarkers in Breast Cancer: A Systematic Review and Meta-Analysis

    by Nahad Al-Mahrouqi, Hasan Al-Sayegh, Shoaib Al-Zadjali, Aafaque Ahmad Khan

    Breast cancer continues to be the most frequently diagnosed cancer among women worldwide and remains a leading cause of cancer-related mortality. Despite advances in imaging and biopsy-based approaches, current diagnostic methods are invasive, costly, and often insufficient to capture the molecular heterogeneity of tumors. Extracellular vesicles (EVs) have emerged as promising non-invasive biomarkers owing to their role in intercellular communication and their enrichment with tumor-specific cargo. This study conducted a systematic review and meta-analysis of published literature to investigate proteomic alterations in EVs derived from breast cancer samples. From an initial 1097 records screened, four eligible studies were identified, reporting 628 differentially expressed proteins, of which 38 were consistently observed across multiple datasets. Functional enrichment analyses revealed predominant localization of these proteins to vesicle-associated compartments and significant involvement in biological processes related to cell growth, immune regulation, and tumor progression. Pathway analysis further highlighted integrin-mediated interactions, platelet activation, and hemostasis pathways as key molecular mechanisms represented within breast cancer EVs. Overall, the findings reveal a distinct EV proteomic signature in breast cancer that could support early detection and patient monitoring through minimally invasive testing. Future large-scale and standardized studies are needed to validate these candidate proteins and advance EV proteomics toward clinical application in breast cancer management.


  • Atypical teratoid rhabdoid tumor with extraneural metastases: a case report with genomic analysis

    by Nausheen Yaqoob, Boris Itkin, Syeda Sara Tajammul, Muna Mubarak Al Jabri, Zahida Niaz, Ravikanth Balaji, Ahmed Al Azri, Ibrahim Hassan Alhaddabi, Shoaib Al-Zadjali, Prashant Deshpande

    Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive malignancy localized to the neuroaxis. It predominantly affects infants and young children, with exceedingly rare occurrences in adolescents and young adults. While its central nervous system (CNS) dissemination is common, extraneural metastases are exceptionally rare. We present a case of brain ATRT in a 16-year-old patient who, 8 months after the initial remission, developed an extraneural relapse involving visceral and skeletal sites. This unusual presentation posed significant diagnostic challenges in differentiating relapse from a second primary rhabdoid neoplasm. Comparative genomic analysis using a multigene panel found identical mutations in both the primary CNS tumor and a relapsed lesion, confirming their common clonal origin and ruling out a second de novo malignancy. Our case underscores the importance of awareness about the possibility of systemic relapse of ATRT. To our knowledge, this is the first report of applying comparative genomic profiling to discriminate between metastatic relapse and a second primary. Larger studies are needed to validate this approach in diverse tumor types.

  • Open Access

    Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls

    by Nahad Al-Mahrouqi, Nada Al Shuaili, Shoaib Al-Zadjali, Anoopa Pullanhi, Hamida Al-Barwani, Aida Al-Kindy, Hadeel Al-Sharqi, Khalid Al-Baimani, Mansour Al-Moundhri, Bushra Salman

    Background/Objectives: Pharmacogenomic screening plays a crucial role in optimizing chemotherapy outcomes and minimizing toxicity. Characterizing the baseline distribution of genetic variants in specific populations is essential to inform the prioritization of drug–gene combinations for clinical implementation. The objective of this study was to investigate the distribution of pharmacogenetic variants in 36 genes related to the fluoropyrimidine (FP) pathway among healthy Omani individuals, forming a foundation for future studies in cancer patients receiving FP-based chemotherapy. Methods: Ninety-eight healthy Omani participants aged ≥18 years were recruited at the Sultan Qaboos Comprehensive Cancer Care and Research Center. Whole-blood samples were collected, and genomic DNA was extracted. Targeted next-generation sequencing was performed using a custom Ion AmpliSeq panel covering coding exons and splice-site regions of 36 genes involved in FP metabolism and response. Results: A total of 999 variants were detected across the 36 genes, with 63.3% being heterozygous. The ABCC4 gene had the highest mutation frequency (76 mutations), while DHFR and SMUG1 had the lowest (DPYD, four functionally significant variants were found at frequencies ranging from 1 to 8.2% of the population. Missense mutations were also observed in MTHFR and UGT1A1. Three actionable variants in DPYD and MTHFR, associated with 5-fluorouracil and/or capecitabine response, were identified. Additionally, 27 novel single-nucleotide polymorphisms of unknown clinical significance were detected. Conclusions: This study reveals key pharmacogenetic variants in the Omani population, underscoring the importance of integrating pharmacogenomic testing into routine care to support safer, more personalized chemotherapy in the region.


  • Open Access

    Deciphering Urogenital Cancers through Proteomic Biomarkers: A Systematic Review and Meta-Analysis

    by Aafaque Ahmad Khan, Nahad Al-Mahrouqi, Aida Al-Yahyaee, Hasan Al-Sayegh, Munjid Al-Harthy, Shoaib Al-Zadjali

    Urogenital cancers, which include prostate, bladder, and kidney malignancies, exert a substantial impact on global cancer-related morbidity and mortality. Proteomic biomarkers, emerging as valuable tools, aim to enhance early detection, prognostic accuracy, and the development of personalized therapeutic strategies. This study undertook a comprehensive systematic review and meta-analysis of the existing literature investigating the role and potential of proteomic biomarkers in plasma, tissue, and urine samples in urogenital cancers. Our extensive search across several databases identified 1879 differentially expressed proteins from 37 studies, signifying their potential as unique biomarkers for these cancers. A meta-analysis of the significantly differentially expressed proteins was executed, accentuating the findings through visually intuitive volcano plots. A functional enrichment analysis unveiled their significant involvement in diverse biological processes, including signal transduction, immune response, cell communication, and cell growth. A pathway analysis highlighted the participation of key pathways such as the nectin adhesion pathway, TRAIL signaling pathway, and integrin signaling pathways. These findings not only pave the way for future investigations into early detection and targeted therapeutic approaches but also underscore the fundamental role of proteomics in advancing our understanding of the molecular mechanisms underpinning urogenital cancer pathogenesis. Ultimately, these findings hold remarkable potential to significantly enhance patient care and improve clinical outcomes.


  • Molecular blood group screening in Omani blood donors

    by Arwa Z. Al‐Riyami, Dina Al Hinai, Mohammed Al‐Rawahi, Saif Al‐Hosni, Shoaib Al‐Zadjali, Ali Al‐Marhoobi, Murtadha Al‐Khabori, Hamad Al‐Riyami, Gregory A. Denomme

    Background and Objectives: Blood group genotyping has been used in different populations. This study aims at evaluating the genotypes of common blood group antigens in the Omani blood donors and to assess the concordance rate with obtained phenotypes.Material and Methods: Blood samples from 180 Omani donors were evaluated. Samples were typed by serological methods for the five blood group systems MNS, RH (RHD/RHCE), KEL, FY and JK. Samples were genotyped using RBC‐FluoGene vERYfy eXtend kit (inno‐train©). Predicted phenotypic variants for 70 red blood cell antigens among the MNS, RH (RHD/RHCE), KEL, FY, JK, DO, LU, YT, DI, VEL, CO and KN blood group systems were assessed.Results: Simultaneous phenotype and genotype results were available in 130 subjects. Concordance rate was >95% in all blood group systems with exception of Fy(b+) (87%). Homozygous GATA‐1 mutation leading to erythroid silencing FY*02N.01 (resulting in the Fy(b‐)ES phenotype) was detected in 81/112 (72%) of genotyped samples. In addition, discrepant Fyb phenotype/genotype result was obtained in 14/112 samples; 13 of which has a heterozygous GATA‐1 mutation and one sample with a wild GATA genotype. D and partial e c.733C>G variants expressing the V+VS+ phenotype were found in 22/121 (18.2%) and 14/120 (11.7%) of the samples, respectively. Di(a‐b+), Js(a‐b+), Yt(a+b‐) and Kn(a+b‐) genotype frequencies were 99.4%, 95.8%, 91.9% and 97.7%, respectively.Conclusion: In conclusion, we report a high frequency of FY*02N.01 allele due to homozygous c.‐67T>C GATA‐1 single‐nucleotide variation. This is the first study reporting the detailed distribution of common and rare red cell genotypes in Omani blood donors.